Dermatological Indications May Drive Humira Growth, Abbott Says
This article was originally published in The Pink Sheet Daily
Executive Summary
An approval for psoriatic arthritis could occur in the second half of 2005; the supplemental BLA has an estimated user fee date in October. First quarter U.S. Humira sales were down from the previous quarter due to competition from Amgen/Wyeth's Enbrel and "disappointing" penetration of the early RA market, Abbott says.